Scholarlink

<p>Peripheral T cell lymphomas (PTCLs) are a diverse group of aggressive malignancies that arise from mature, post-thymic T cells. Recent genomic and mechanistic studies reveal that these cancers frequently ‘hijack’ signalling pathways that normally govern T cell activation at the immunological synapse. Specifically, numerous gain-of-function alterations in TCR proximal regulators and mediators of antigen-induced NF-κB activation, as well as mutations or overexpression of co-stimulatory receptors and dysregulated cytokine receptor signalling, promote the constitutive proliferation and survival of malignant clones. Conversely, loss-of-function mutations in <i>PDCD1</i> or disruption of PD1-mediated inhibitory control, coupled with altered metabolic and epigenetic reprogramming, have emerged as a major tumour-suppressor mechanism in PTCL pathogenesis. This framework conceptualizes PTCLs as ‘cancers of aberrant immune synapse signalling pathways’ and posits that genetic dissection of PTCL pathogenesis can uncover fundamental aspects of T cell biology to guide the design of safer, more effective next-generation T cell therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

T cell lymphomas: cancers of aberrant immune synapse signalling

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Peter A. Tauber,
  • Jürgen Ruland

摘要

Peripheral T cell lymphomas (PTCLs) are a diverse group of aggressive malignancies that arise from mature, post-thymic T cells. Recent genomic and mechanistic studies reveal that these cancers frequently ‘hijack’ signalling pathways that normally govern T cell activation at the immunological synapse. Specifically, numerous gain-of-function alterations in TCR proximal regulators and mediators of antigen-induced NF-κB activation, as well as mutations or overexpression of co-stimulatory receptors and dysregulated cytokine receptor signalling, promote the constitutive proliferation and survival of malignant clones. Conversely, loss-of-function mutations in PDCD1 or disruption of PD1-mediated inhibitory control, coupled with altered metabolic and epigenetic reprogramming, have emerged as a major tumour-suppressor mechanism in PTCL pathogenesis. This framework conceptualizes PTCLs as ‘cancers of aberrant immune synapse signalling pathways’ and posits that genetic dissection of PTCL pathogenesis can uncover fundamental aspects of T cell biology to guide the design of safer, more effective next-generation T cell therapies.